SLC34A1 and hypercalcemia disease: If there is a diagnosis of hypercalcemia, hypercalciuria, nephrolithiasis, nephrocalcinosis, CYP24A1 or SLC34A1 gene mutations or other form of vitamin D hypersensitivity in a patient or his/her family members, the supplementation should be carried out individually, and controlled by parameters of calcium-phosphate metabolism, particularly calcemia, PTH, calciuria, 25(OH)D and 1,25(OH)2D.